NEW YORK (GenomeWeb News) – Madison, Wis.-based Cellular Dynamics and Sittingbourne, England-based VivoMedica today said that they have launched a consortium to validate a human cell model and analysis system, based on the firms' technologies, for preclinical cardiotoxicity testing of drug candidates.
The firms said the consortium is being launched this week in France at the Safety Pharmacology Society 9th Annual Meeting. The firms hope to enlist pharmaceutical companies in validating the human cardiac model.
Specifically, the consortium aims to validate the testing system using Cellular Dynamics' iCell Cardiomyocytes and VivoMedica's DrugPrint analysis system. They said that extracellular micro-electrode array recordings from induced pluripotent stem cell-derived human cardiomyocytes will be analyzed using VivoMedica's electrical waveform analysis technology.
The partners believe this approach will identify drug-induced changes that indicate the arrhythmogenic potential of drug candidates under investigation.